Biotech RadarJobs updated

COMPANY

NexImmune Inc.

neximmune.com ↗

Clinical Phase 2

Profile checked Oct 10, 2026

Keywords: Relapsed Refractory Multiple Myeloma Oropharyngeal Cancer Human Papilloma Virus Head and Neck Cancer Head and Neck Squamous Cell Carcinoma Oropharyngeal Squamous Cell Carcinoma Metastatic Oropharyngeal Cancer Head and Neck Cancer Metastatic HPV-Related Squamous Cell Carcinoma HPV-Related Mucosal Head and Neck Squamous Cell Carcinoma Relapsed Oropharyngeal SCC Refractory Oropharyngeal Squamous Cell Carcinoma Acute Myeloid Leukemia Myelodysplastic Syndrome NEXI-002 T Cells

3Trials (company is sponsor)

Timeline

  1. Trial start Phase 1: Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers source ↗
  2. Trial start Phase 1/Phase 2: Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma source ↗
  3. Trial start Phase 1/Phase 2: Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT source ↗

Clinical trials (lead sponsor) 3

RecordTitlePhaseStatusStartPrimary completion
NCT04505813Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple MyelomaPhase 1/Phase 2SuspendedAug 17, 2020Nov 30, 2024 (estimated)
NCT05582590Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal CancersPhase 1Not yet recruitingMar 31, 2025Jul 1, 2026 (estimated)
NCT04284228Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCTPhase 1/Phase 2Unknown status (ClinicalTrials.gov)Feb 20, 20202024-10 (estimated)
Feedback